Clinical features and prognosis of patients with myeloid neoplasms harboring t(7;11)(p15;p15) translocation: a single-center retrospective study.

Autor: Liu L; Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.; Zhejiang Province Key Laboratory of Hematology Oncology, Diagnosis, and Treatment, Hangzhou, China., Zhao S; Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China., Wang L; Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China., Xu H; Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.; Zhejiang Province Key Laboratory of Hematology Oncology, Diagnosis, and Treatment, Hangzhou, China., Chen Z; Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.; Zhejiang Province Key Laboratory of Hematology Oncology, Diagnosis, and Treatment, Hangzhou, China., Tu J; Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.; Zhejiang Province Key Laboratory of Hematology Oncology, Diagnosis, and Treatment, Hangzhou, China., Huang J; Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.; Zhejiang Province Key Laboratory of Hematology Oncology, Diagnosis, and Treatment, Hangzhou, China., Jin J; Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. jiej0503@zju.edu.cn.; Zhejiang Province Key Laboratory of Hematology Oncology, Diagnosis, and Treatment, Hangzhou, China. jiej0503@zju.edu.cn., Tong H; Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. tonghongyan@zju.edu.cn.; Zhejiang Province Key Laboratory of Hematology Oncology, Diagnosis, and Treatment, Hangzhou, China. tonghongyan@zju.edu.cn.
Jazyk: angličtina
Zdroj: BMC cancer [BMC Cancer] 2024 Aug 05; Vol. 24 (1), pp. 955. Date of Electronic Publication: 2024 Aug 05.
DOI: 10.1186/s12885-024-12679-8
Abstrakt: Background: For myeloid neoplasms with t(7;11)(p15;p15) translocation, the prognosis is quite dismal. Because these tumors are rare, most occurrences are reported as single cases. Clinical results and optimal treatment approaches remain elusive. This study endeavors to elucidate the clinical implications and prognosis of this cytogenetic aberration.
Methods: This study retrospectively analyzed 23 cases of myeloid neoplasm with t(7;11)(p15;p15). Clinicopathological characteristics, genetic alterations, and outcomes were evaluated, and the Kaplan-Meier method was employed to construct survival curves.
Results: Of these, nine cases were newly diagnosed acute myeloid leukemia (ND AML), seven presented with relapsed refractory AML (R/R AML), four had myelodysplastic syndrome (MDS), two had secondary AML, and one exhibited a mixed germinoma associated with MDS. Patients with t(7;11)(p15;p15) in AML were primarily younger females who preferred subtype M2. Interestingly, these patients had decreased hemoglobin and red blood cell counts, along with markedly elevated levels of lactic dehydrogenase and interleukin-6, and exhibited the expression of CD117. R/R AML patients exhibited a higher likelihood of additional chromosome abnormalities (ACAs) besides t(7;11). WT1 and FLT3-ITD were the most commonly found mutated genes, and 10 of those instances showed evidence of the NUP98::HOXA9 fusion gene. The composite complete remission rate was 66.7% (12/18), while the cumulative graft survival rate was 100% (4/4). However, the survival outcomes were dismal. Interestingly, the median overall survival for R/R AML patients was 4.0 months (95% CI: 1.7-6.4). Additionally, the type of AML diagnosis or the presence of ACAs or molecular prognostic stratification did not significantly influence clinical outcomes (p = 0.066, p = 0.585, p = 0.570, respectively).
Conclusion: Myeloid leukemia with t(7;11) exhibits unique clinical features, cytogenetic properties, and molecular genetic characteristics. These survival outcomes were dismal. R/R AML patients have a limited lifespan. For myeloid patients with t(7;11), targeted therapy or transplantation may be an effective course of treatment.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje